Projekt
COSMIC 312
Abgeschlossen · 2019 bis 2020
Semela David, Stillhard Roman
Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2019
Ende
2020
Finanzierungsart
Industrie
Studiendesign
This is a multicenter, randomized, open-label, controlled Phase 3 trial of cabozantinib in
combination with atezolizumab versus sorafenib in subjects with advanced HCC who have not
received previous systemic anticancer therapy.
Kurzbeschreibung/Zielsetzung
A Randomized, Controlled Phase 3 Study of Cabozantinib
(XL184) in Combination with Atezolizumab versus Sorafenib
in Subjects with Advanced Hepatocellular Carcinoma Who
Have Not Received Previous Systemic Anticancer Therapy
Randomisation 2:1:1:1
Cabozantinib + Atezolizumab
Sorafenib
Cabozantinib